» Articles » PMID: 27001893

Targeted Delivery of SiRNA to Activated T Cells Via Transferrin-polyethylenimine (Tf-PEI) As a Potential Therapy of Asthma

Overview
Specialty Pharmacology
Date 2016 Mar 23
PMID 27001893
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Asthma is a worldwide health problem. Activated T cells (ATCs) in the lung, particularly T helper 2 cells (Th2), are strongly associated with inducing airway inflammatory responses and chemoattraction of inflammatory cells in asthma. Small interfering RNA (siRNA) as a promising anti-sense molecule can specifically silence inflammation related genes in ATCs, however, lack of safe and efficient siRNA delivery systems limits the application of siRNA as a therapeutic molecule in asthma. Here, we designed a novel pulmonary delivery system of siRNA, transferrin-polyethylenimine (Tf-PEI), to selectively deliver siRNA to ATCs in the lung. Tf-PEI polyplexes demonstrated optimal physicochemical properties such as size, distribution, zeta-potential, and siRNA condensation efficiency. Moreover, in vitro studies showed significantly enhanced cellular uptake and gene knockdown mediated by Tf-PEI polyplexes in human primary ATCs. Biodistribution of polyplexes in a murine asthmatic model confirmed that Tf-PEI polyplexes can efficiently and selectively deliver siRNA to ATCs. In conclusion, the present work proves the feasibility to target ATCs in asthma via Tf receptor. This strategy could potentially be used to design an efficient siRNA delivery system for asthma therapy.

Citing Articles

Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.

Cui L, Yang Y, Hao Y, Zhao H, Zhang Y, Wu T Clin Rev Allergy Immunol. 2025; 68(1):12.

PMID: 39928241 PMC: 11811441. DOI: 10.1007/s12016-024-09019-w.


Biomaterials for in situ cell therapy.

Wang C, Wang S, Kang D, Dong Y BMEmat. 2024; 1(3).

PMID: 39574564 PMC: 11581612. DOI: 10.1002/bmm2.12039.


In Vitro Photoselective Gene Transfection of Hepatocellular Carcinoma Cells with Hypericin Lipopolyplexes.

Shah H, Schluter S, Amin M, Abu Dayyih A, Engelhardt K, Pinnapireddy S ACS Appl Mater Interfaces. 2024; 16(33):43416-43429.

PMID: 39121233 PMC: 11345729. DOI: 10.1021/acsami.4c10438.


Role of Hydrophobic Modification in Spermine-Based Poly(β-amino ester)s for siRNA Delivery and Their Spray-Dried Powders for Inhalation and Improved Storage.

Jin Y, Wang X, Kromer A, Muller J, Zimmermann C, Xu Z Biomacromolecules. 2024; 25(7):4177-4191.

PMID: 38866384 PMC: 11238323. DOI: 10.1021/acs.biomac.4c00283.


Tailoring lipid nanoparticles for T-cell targeting in allergic asthma: Insights into efficacy and specificity.

Jurgens D, Muller J, Nguyen A, Merkel O Eur J Pharm Biopharm. 2024; 198:114242.

PMID: 38442794 PMC: 7616735. DOI: 10.1016/j.ejpb.2024.114242.


References
1.
Breunig M, Lungwitz U, Liebl R, Goepferich A . Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A. 2007; 104(36):14454-9. PMC: 1964826. DOI: 10.1073/pnas.0703882104. View

2.
Kumar P, Ban H, Kim S, Wu H, Pearson T, Greiner D . T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008; 134(4):577-86. PMC: 2943428. DOI: 10.1016/j.cell.2008.06.034. View

3.
Grayson A, Doody A, Putnam D . Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res. 2006; 23(8):1868-76. DOI: 10.1007/s11095-006-9009-2. View

4.
Rettig G, Behlke M . Progress toward in vivo use of siRNAs-II. Mol Ther. 2011; 20(3):483-512. PMC: 3293614. DOI: 10.1038/mt.2011.263. View

5.
Lee J, Yun K, Choi C, Shin S, Ban H, Rhim T . T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem. 2012; 23(6):1174-80. DOI: 10.1021/bc2006219. View